Recently added

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Strickler, John; Cercek, Andrea; Heinemann, Volker; Nakamura, Yoshiaki; Raghav, Kanwal; Bekaii-Saab, Tanios; Tabernero, Josep (Taylor & Francis, 2024-12-26)

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Grünwald, Viktor; McKay, Rana R.; Buchler, Tomas; Eto, Masatoshi; Park, Se Hoon; Takagi, Toshio; Suárez, Cristina (Wiley, 2025-04-01)

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

de Miguel Luken, Maria; de velasco, Guillermo; Martín Liberal, Juan Jesús; Oberoi, Arjun ; MELERO BERMEJO, IGNACIO; GARRALDA, Elena; Joerger, Markus; Hernando-Calvo, Alberto (Nature Portfolio, 2025-12-11)

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

zhang, xiaohu; Diazgranados Daza, Adriana Paola; Ortega Bertran, Sara; FERNÁNDEZ RODRÍGUEZ, JUANA; Magallon-Lorenz, Miriam; Creus, Edgar; Valverde, Claudia María; Romagosa, Cleofé (American Association for Cancer Research, 2025-03-03)

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, Myung-Ju; Tanaka, Kentaro; Cornelissen, Robin; Girard, Nicolas ; Pons-Tostivint, Elvire; Paz-Ares, Luis; FELIP, ENRIQUETA (American Society of Clinical Oncology, 2025-01-20)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer ﻿

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial ﻿

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours ﻿

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models ﻿

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study ﻿

MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study